B
Barry A. Condie
Researcher at Wistar Institute
Publications - 10
Citations - 1341
Barry A. Condie is an academic researcher from Wistar Institute. The author has contributed to research in topics: Antimicrobial peptides & Minimum inhibitory concentration. The author has an hindex of 8, co-authored 10 publications receiving 1248 citations. Previous affiliations of Barry A. Condie include University of Düsseldorf & Florey Institute of Neuroscience and Mental Health.
Papers
More filters
Journal ArticleDOI
The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding.
TL;DR: The data suggest that drosocin and pyrrhocoricin binding prevents the frequent opening and closing of the multihelical lid over the peptide-binding pocket of DnaK, permanently closes the cavity, and inhibits chaperone-assisted protein folding.
Journal ArticleDOI
Interaction between Heat Shock Proteins and Antimicrobial Peptides
Laszlo Otvos,Rogers Me,Consolvo Pj,Barry A. Condie,Sándor Lovas,Philippe Bulet,Magdalena Blaszczyk-Thurin +6 more
TL;DR: All three antibacterial peptides strongly interacted with two bacterial lipopolysaccharide preparations in solution, indicating that the initial step of the bacterial killing cascade proceeds through LPS-mediated cell entry.
Journal ArticleDOI
Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sunflower seeds and an acyclic permutant
Michael L. J. Korsinczky,Horst Joachim Schirra,K.J. Rosengren,Jenny West,Barry A. Condie,Laszlo Otvos,Marilyn A. Anderson,David J. Craik +7 more
TL;DR: The lack of a major conformational change upon binding suggests that the structure of SFTI-1 is rigid and already pre-organized for maximal binding due to minimization of entropic losses compared to a more flexible ligand, making it an ideal platform for the design of small peptidic pharmaceuticals or pesticides.
Journal ArticleDOI
Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin.
Goran Kragol,Ralf Hoffmann,Michael A. Chattergoon,Sándor Lovas,Mare Cudic,Philippe Bulet,Barry A. Condie,K. Johan Rosengren,Luis J. Montaner,Laszlo Otvos +9 more
TL;DR: Findings highlighted pyrrhocoricin's suitability for combating intracellular pathogens and raised the possibility that the proline-rich antibacterial peptides can deliver drug leads into mammalian cells.
Journal ArticleDOI
Development of novel antibacterial peptides that kill resistant isolates.
Mare Cudic,Barry A. Condie,Daniel J. Weiner,Daniel J. Weiner,Elena S. Lysenko,Zhi Quan Xiang,Insug O,Philippe Bulet,Laszlo Otvos +8 more
TL;DR: The designed dimers showed improved stability in mammalian sera compared to the native analog and a single dose of a dimeric pyrrhocoricin analog reduced the bacteria in the bronchoalveolar lavage when delivered intranasally.